Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 15/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | MERTK | Q12866 | 2/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15826967 | 0.88 | AXL (0.54) | ACVRL1AXLMERTKTYRO3KDM4E | |
| SCHEMBL19701791 | 0.80 | ACVRL1 (0.44) | ACVRL1AXLMERTKTYRO3 | |
| SCHEMBL19701790 | 0.79 | PIK3CD (0.54) | ACVRL1AXLMERTKTYRO3 | |
| SCHEMBL19701787 | 0.77 | AXL (0.41) | ACVRL1AXLMERTKTYRO3ALDH1A1 | |
| SCHEMBL66503 | 0.75 | ALDH1A1 (0.43) | ACVRL1AXLMERTKTYRO3ALDH1A1 | |
| SCHEMBL12365553 | 0.75 | ALDH1A1 (0.43) | ACVRL1AXLMERTKTYRO3KDM4E | |
| SCHEMBL19701781 | 0.74 | PIK3CD (0.51) | ACVRL1AXLMERTKTYRO3 | |
| SCHEMBL279151 | 0.74 | FGFR1 (0.49) | ACVRL1KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL64680 | 0.74 | ALDH1A1 (0.42) | ACVRL1AXLMERTKTYRO3ALDH1A1 | |
| SCHEMBL19701785 | 0.72 | PIK3CD (0.46) | ACVRL1AXLMERTKTYRO3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | ACVRL1 941/4885AXL 1951/4885MERTK 1749/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ACVRL1 963/4885AXL 2194/4885MERTK 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.